June 13, 2011 (London, United Kingdom) — Contrary to expectation, progression-free survival in patients with multiple myeloma is longer in patients who receive high-dose melphalan (Alkeran, GlaxoSmithKline) and undergo autologous stem cell transplantation (ASCT) than in those treated with the ...
high-dose-melphalan网络高剂量化学治疗 网络释义 1. 高剂量化学治疗 有学者报告,以高剂量化学治疗(high-dose melphalan)合并自体骨髓移植来治疗多发性骨髓瘤,可以得到较高的缓解率。甚…tw.myblog.yahoo.com|基于15个网页© 2025 Microsoft 隐私声明和 Cookie 法律声明 广告 帮助 反馈...
et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37, 917–922 (2006). https://doi.org/10.1038/sj...
Recent retrospective analyses show that patients who attain MRD negativity have similar long term outcomes regardless of early or delayed high dose melphalan with autologous stem cell support (HDM-ASCT). Given HDM-ASCT toxicity, not "overtreating" would be beneficial. Short of data from future ...
The strategy of giving Darbe around 1 month after high-dose melphalan (HDM) doesn't reduce RBC transfusion requirement.doi:10.4236/ojbd.2012.23012Massimo MartinoIda CalleaTiziana MoscatoAntonella PontariRoberta FedeleOpen Journal of Blood Diseases...
High-dose melphalan (HDM) with peripheral blood stem cell transplant (PBSCT) is a common treatment for patients with multiple myeloma (MM) and more recentl... Schuh,A,Dandridge,... - 《Bone Marrow Transplantation》 被引量: 18发表: 1999年 case report encephalopathy complicating high-dose melpha...
Of the 13 286 autologous haematopoietic cell transplant procedures reported in the US in 2010–2012 for plasma cell disorders, 10 557 used single agent, high-dose melphalan. Despite 30 years of clinical and pharmacokinetic (PK) experience with high
Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Childhood acute myeloid leukemia (AML) has a poor prognosis with standard chemotherapy. Allogeneic bone marrow transplantation (BMT) in ...
Oral mucositis (OM) is one of the most frequent adverse events of high-dose conditioning chemotherapy with melphalan prior to autologous hematopoietic stem cell transplantation (AHSCT). It significantly reduces the patients’ quality of life. One of the
High-dose melphalan (MEL200) followed by autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces responses in MM resistant to other alkylators. Our prior Phase I trial adding bendamustine to MEL200 transplant conditioning resulted in no...